TcBuster transposase for robust delivery of multicistronic therapeutic cargo – Scientific Poster

Overview
TcBuster-MTM (TcB-MTM) is a commercially available non-viral transposase-based editing platform that overcomes current viral limitations. TcBuster is found in the red flour beetle and is a member of the hAT family of transposases. Using directed evolution, we engineered a hyperactive mutant (TcB-M) that has improved transposition rates using less mRNA transposase and NanoplasmidTM DNA transposon.
What this paper found
A directed-evolution mutant of the TcBuster transposase, TcB-M, drove cargo integration above 60 per cent in primary T cells and peripheral blood NK cells without sacrificing cell growth or raising clonal dominance concerns. The mutant came out of a mammalian high-throughput screen of more than 3 million variants, a far larger library than those behind piggyBac or Sleeping Beauty. Head-to-head against both, using an EF1a-CD19-DHFR-eGFP transposon electroporated into CD4+CD8+ T cells and read on day 7 across at least three donors, TcB-M reached higher transposition with less transposon and gentler programs. It also integrated more randomly than lentivirus, and runs from vector map to GMP transposon in roughly 6-8 months.
Study details
- Authors
- Kirsti L. Walker, Bryan J. Jones, Kalyani Kota, Katie Hornberger, Neil Otto
- Institution
- Cell & Gene Therapy & Protein Sciences, Bio-Techne, Minneapolis, Minnesota · Department of Pediatrics, University of Minnesota, Minneapolis, MN · Masonic Cancer Center, University of Minnesota, Minneapolis, MN · Center for Genome Engineering, University of Minnesota, Minneapolis, MN
- Cell type(s)
- CAR T Cells, NK Cells, T-Cells
Explore related
Building a similar workflow?
Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.